Amy Walsh
Senior Vice President, External ManufacturingRegeneron Pharmaceuticals
PharmaceuticalsView Profile →Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer · Vertex Pharmaceuticals
Carmen Bozic is executive vice president of Global Medicines Development and Medical Affairs and chief medical officer at Vertex Pharmaceuticals. She previously spent more than twenty years at Biogen, leading clinical development and related functions.
Last reviewed: Oct 31, 2026
Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Vertex Pharmaceuticals
Last Reviewed: October 31, 2026
Carmen Bozic is executive vice president of Global Medicines Development and Medical Affairs and chief medical officer at Vertex Pharmaceuticals. She previously spent more than twenty years at Biogen, leading clinical development and related functions.
Bozic trained in internal medicine at McGill University, where she also served as chief resident, and completed a combined pulmonary and critical care fellowship at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. Before entering industry, she researched inflammatory responses at Boston Children’s Hospital’s Ina Sue Perlmutter Cystic Fibrosis Research Laboratory and worked as an associate physician at Beth Israel Deaconess and Harvard Medical School.
She spent more than twenty years at Biogen, progressing to senior vice president of global development. Her responsibilities included clinical development, drug safety, preclinical safety, regulatory affairs, clinical operations and biometrics across an organization spanning the United States, Europe and Japan.
Her development work at Biogen included therapies for multiple sclerosis, hemophilia and spinal muscular atrophy. These programs included Tysabri, Tecfidera, Eloctate, Alprolix and Spinraza.
Bozic joined Vertex in May 2019 as senior vice president and head of global clinical development. In October that year, she became executive vice president of Global Medicines Development and Medical Affairs. She added the chief medical officer role on April 1, 2020, when Reshma Kewalramani became CEO.
She now oversees clinical development, medical affairs, drug safety, global clinical operations and biometrics. Her professional service has included the FDA’s Risk Communication Advisory Committee and PhRMA’s Clinical and Preclinical Development Committee; she is also a member of Akili Interactive’s Clinical Advisory Committee.
Bozic received her medical degree from McGill University, where she completed internal medicine residency and served as chief resident. She later completed pulmonary and critical care fellowship training in Boston.